Method for intestinal flora stimulation

FIELD: medicine.

SUBSTANCE: at that, this composition is adapted for enteral administration to infants. The composition comprises at least one microorganism and at least non-digestible galactooligosaccharides, wherein the said microorganism is at least one species of Bifidobacteria selected from the group consisting of Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium bifidum, Bifidobacterium catenulatum, Bifidobacterium adolescentis and Bifidobacterium longum.

EFFECT: invention allows to stimulate healthy development of intestinal flora in these infants.

9 cl, 2 tbl, 6 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention is intended for prevention of post-infectious irritable bowel syndrome (PI-IBS). Peroral intake of autoprobiotic, representing individual lactic product, prepared on the basis of Enterococcus faecium strain, and containing 108 CFU in 1 ml of product. Inoculation of bacteria from patient's feces on selective nutritional medium is performed, with further culture growing in selective nutritional medium, identification and selection of colonies, typical for Enterococcus faecium, obtaining pure culture of Enterococcus faecium and specification of species and content of pathogenecity factors by method of polymerase chain reaction, selection of apatogenic clones of Enterococcus faecium, corresponding to standards of genetic safety and physiological functionality, which are used to prepare lactic starter culture. Autoprobiotic is introduced in dose not less than 100 ml/day, with course constituting not fewer than 10 days. Selected apathogenic clones of Enterococcus faecium are deposited in cryostorage at temperature not higher than -75°C with storage term not longer than 1 year. Enterococcus-agar is used as selective nutritional medium.

EFFECT: method makes it possible to increase efficiency of prophylaxis of PI-IBS patients due to reduction of its development frequency.

3 cl, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claim describes prolonged release formulations containing an active ingredient presented by octreotide or its pharmaceutically acceptable salt and three various linear polymers of poly(lactide-co-glycolic acid) (PLGA). The first PLGA has the lactide:glycolic acid relation of 65:35; the second PLGA has the lactide:glycolic acid relation of 75:25; the third PLGA has the lactide:glycolic acid relation of 85:15. The octrotide composition containing three various linear polymers of PLGA is characterized by the plasma octreotide concentration of low variability over the period of time making more than three months.

EFFECT: composition is applicable for the prolonged supporting therapy of the patients suffering acromegalia and for treating diarrhoea and congestions associated with malignant carcinoids and tumours producing vasoactive intestinal peptides (VIPoma-like tumours).

18 cl, 4 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary medicine and can be used for treating and preventing gastrointestinal diseases accompanied by diarrhoeas in newborn calves Substance of the method consists in adding the oral administration of a therapeutic mixture of antibacterial, antitoxic and rehydration agents with the intramuscular injections of immunofan in a single dose of 1 ml 2-3 times every second day.

EFFECT: method provides increasing the therapeutic and preventive effectiveness in acute gastrointestinal diseases in newborn calves.

2 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel macrocyclic alkylammonium derivatives of 6-methyluracil of formula (1). The compounds have anticholinesterase activity and can be used for pharmacological correction of synaptic defects which cause Alzheimer's disease, myasthenia gravis and other forms of pathological muscle weakness. The compounds can be used when treating glaucoma, intestinal atony, alcoholism, schizophrenia, manic-depressive psychosis, traumatic brain injury, sleep disorders, etc. In formula (1) X=NO2, Y=(CH2)4 (1a); X=CN, Y=(CH2)4 (1b); X=NO2, Y=C6H4 (1c); X=CN, Y=C6H4 (1d).

EFFECT: improved properties of compounds.

2 cl, 2 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gastroenterology, and can be used for providing the higher clinical effectiveness in the patients suffering dyspepsia syndrome combined with overweight. The method involves measuring an anxiety level (HARS) and a depression level (HDRS) according to Hamilton rating scales, assessing nutritional status by bioimpedancemetry, a degree of manifestation of sleep disorders, measuring glucose, testing glucose tolerance, immunoreactive insulin, cholesterol, high-density lipoprotein (HDLP), triglyceride in venous blood. If the patient is observed to suffer dyslipidemia and impaired glucose tolerance or variations of immunoreactive insulin, the preparation Dibikor is administered in a dose of 500 mg a day for three months. The patient suffering dyslipidemia and both of the disorders stated above requires administering Dibikor 1000 mg a day for three months. If the patient suffers an overweight with a body weight index falling within the range of 27 to 29.9 standard units and an active cell mass (ACM) percentage of 45 to 55 per cent as shown by bioimpedancemetry, the preparation Dietressa is administered in a dose of 1 tablet 3-4 times a day for three to six months. If the patient suffers an overweight with a body weight index falling within the range of 27 to 29.9 standard units and an active cell mass (ACM) percentage of 45 to 55 per cent as shown by bioimpedancemetry, the preparation Dietressa is administered in a dose of 2 tablet 3-4 times a day for three to six months. If the patient suffers mild and moderate sleep disorders and shows an emotive type of eating behaviour combined with mild affective disorders, the anti-depressant Valdoxane in a single dose of 25 mg a day for the night for two weeks. The course of the disease is followed by the anxiety and depression levels two weeks after the beginning of the therapy, with the positive progression of the diseases, the 25mg dose of Valdoxane remains unchanged to the end of the therapeutic course for three to six months. If no progression is exhibited, the dose is to be increased to 50 mg a day, and the therapy is continued from four to eight months. If the patient suffers severe sleep disorders and shows an emotive type of eating behaviour combined with moderate affective disorders, the anti-depressant Valdoxane in a single dose of 50 mg a day for the night for two to three months.

EFFECT: in each specific case, the method enables providing faster reduction of the clinical symptoms, including body fat weight reduction and active cell mass and water normalisation, normalising circadian rhythms of the vegetative balance, as well as prolonging the remission.

3 tbl, 2 ex

FIELD: veterinary medicine.

SUBSTANCE: agent or stimulation of metabolic processes, prevention and treatment of gastrointestinal diseases in calves in early postnatal period comprises succinic acid as the energy stimulant, beet molasses as carbohydrate component, methionine as the stimulant of the digestive system, iodinol as the anti-infective component, and water in the following ratio of components, based on 0.5 litre: succinic acid 5.0 g; beet molasses 150.0 ml; methionine 2.0 g; iodinol 30-50 ml; water - the rest.

EFFECT: improvement of agent efficiency.

5 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to paediatrics and neonatology, and can be used for treating small premature infants at the hospital stage of developmental care. A therapeutic complex comprises administering a probiotic preparation into the newborns. The preparation is presented with a liquid probiotic containing E.faecium L3 109 CFU in 1 ml. If the enteral nutrition volume of the newborn is 5 ml or more, this preparation is orally administered in a dose of 0.5 ml 3 times a day for 14 days.

EFFECT: method is effective in children with a very low body weight, promotes normalising the intestinal microflora and reducing a rate of manifestations of infectious complications.

2 ex, 3 dwg, 3 tbl

FIELD: chemistry.

SUBSTANCE: invention provides crystalline solid form of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalin-2-ylamino)-2-cyclohexylmethyl-butyric acid or crystalline hydrochloride of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalin-2-ylamino)-2-cyclohexylmethyl-butyric acid. Invention relates to pharmaceutical composition, possessing antagonistic activity with respect to mu-opioid receptor, which contains therapeutically effective quality of crystalline solid form.

EFFECT: invention provides methods of applying claimed crystalline solid forms in treatment of diseases associated with activity of mu-opioid receptors and methods of obtaining claimed crystalline solid forms.

27 cl, 9 dwg, 17 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science. A preparation for the prevention of diarrhoeas in newborn calves containing acid hydrolysate of animal blood, lactic, benzoic, succinic acids, additionally contains acetic acid, in the following ratio, wt %: acetic acid 0.4-0.5, lactic acid 0.05-0.06, benzoic acid 0.04-0.05, succinic acid 0.02-0.03, acid hydrolysate of animal blood - the rest.

EFFECT: invention provides a lower probability of diarrhoeas in the newborn calves and reducing a mortality rate.

3 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and may be used for relieving abdominal murmur. That is ensured by the oral administration of the bacteria Bifidobacterium animalis in dose 1×109 CFU a day. The bacteria are administered every day, for at least 15 days.

EFFECT: method provides relieving abdominal murmur in a healthy individual that is ensured by the developed dose schedule and specific rate of administration of the above prebiotic.

10 cl, 1 ex

FIELD: biotechnology.

SUBSTANCE: strain is deposited in the State collection of pathogenic microorganisms "SCIM-Obolensky" under the number F-11. The culture fluid centrate obtained as a result of culturing of said the strain on the liquid nutrient medium has high activity against anthrax causative agent. The zone of inhibition of growth of Bacillus anthracis is 20-25 mm and 35-45 mm when the culture fluid centrate of the said strain is used in an amount of 10 mcl and 100 mcl, respectively.

EFFECT: strain of micromycete Trichoderma hamatum has antibacterial activity against anthrax causative agent Bacillus anthracis.

4 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science and aims at controlling demodectic mange in cattle. As an insectoacaricide, a composition is used in the following mixture ratio, wt %: abamectin - 0.1; fipronil - 0.5; dimehyl sulphoxide - 10; ethyl cellulose - 30-40; polyethylene glycol - 1,500 - 16; isopropyl alcohol - the rest up to 100. The composition is used by local applications on the affected areas of the animal's skin.

EFFECT: method enables increasing the therapeutic effectiveness in treating demodectic mange in cattle.

1 tbl, 3 ex

FIELD: veterinary medicine.

SUBSTANCE: insecticidal-acaricidal agent is used as a composition with the following ratio of components, wt %: abamectin - 0.1; fipronyl - 0.5; dimethyl sulfoxide - 10; ethyl-cellulose - 30-40; polyethylene glycol-1500 - 16; isopropyl alcohol - the rest to 100. The composition is used by the method of application to the region of dewlap, shoulder, hip and abdomen in a dose of 20 ml per animal.

EFFECT: method enables to increase the efficiency of protection of cattle from ixodic ticks.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to the strain of Bifidobacterium longum NCIMB 41675, a composition, containing thereof, and a food product, containing the said strain or composition. The claimed strain possesses an ability to induce the production of cytokins and control IL-10:IL-12 ratio is suitable for application in immunomodulation, treatment of an autoimmune disease.

EFFECT: claimed strain, composition and food product possess probiotic properties.

25 cl, 16 dwg, 4 tbl, 8 ex

FIELD: biotechnology.

SUBSTANCE: method of production of probiotic preparation of immobilised bifidobacteria for feeding beef breed cattle is proposed. The bifidobacteria of strain Bifidobacterium longum are grown on a nutrient medium to obtain biotitre of 108-109 CFU/ml. The medium is prepared using the electro-activated cathode water with pH 8-9 and redox potential -400…-500 mV, and with the addition of a stabiliser - serine in an amount of not less than 0.01 wt %. Then bifidobacteria together with the components of the nutrient medium are immobilised on enterosorbent polyphepan.

EFFECT: improved appetite of cattle, digestibility of nutrients of the ration, increase in average daily gain, stimulation of rumen digestion, normalisation of all types of metabolism, acceleration of the settlement of the gastrointestinal tract with normal microflora, reduction of excretion with faeces of pathogenic and opportunistic pathogenic bacteria.

4 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates for composition for treatment or prevention of disorders, associated with reduced level of defensins. Composition contains from 0.005 to 1000 mg of Lactobacillus johnsonii Lal (NCC533, No CNCM 1-1225) per a daily dose, with at least 90% of L. johnsonii Lal (NCC533, No CNCM 1-1225) being transferred into state in which they become non-replicating at temperature110-140°C for 5-30 s.

EFFECT: invention provides enhancement of expression of defensin hBD1 mRNA.

5 cl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with an immunobiological agent for treating urinary bladder cancer, based on BCG vaccine, including a peptidoglycan fragment, which contains diaminopimelic acid as a part of its structure. The group of inventions also deals with a method of applying the claimed immunobiological agent for the treatment of urinary bladder cancer.

EFFECT: group of inventions provides an increased anti-tumour activity.

5 cl, 5 ex, 5 dwg, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to field of pharmaceutics and medicine and deals with composition, possessing property to stimulate antimicrobial defence by increasing expression of endogenous β-defensins, containing strain B. longum NCC 2705, depositary number CNCM 1-2618, with said strain being brought, at least, partially into non-replicable condition by thermal inactivation, processing , at least, about 70°C. Method of stimulating endogenous antimicrobial activity of mammal by increasing expression of endogenous β-defensins, includes introduction of claimed composition.

EFFECT: group of inventions provides increase of efficiency in comparison with live strains.

12 cl, 2 dwg

FIELD: chemistry.

SUBSTANCE: group of inventions relates to biotechnology. Claimed is a strain of Bacillus subtilis Maseca-1, producing a peptide, which has the antimicrobial activity against Micrococcus luteus, Bacillus cereus and Aspergillus flavus. The strain is deposited in ATCC under number PTA-8831. The strain was isolated from pericarp of nixtamalised corn. Also claimed is a method of inhibiting Micrococcus luteus, Bacillus cereus and Aspergillus flavus in a material, containing or subjected to the action of the said microorganisms. The method includes the impact of an effective quantity of the said strain on the material.

EFFECT: group of inventions provides the effective inhibition of the growth of pathogenic microorganisms Micrococcus luteus, Bacillus cereus and Aspergillus flavus.

5 cl, 13 dwg, 7 tbl

FIELD: medicine.

SUBSTANCE: invention is intended for prevention of post-infectious irritable bowel syndrome (PI-IBS). Peroral intake of autoprobiotic, representing individual lactic product, prepared on the basis of Enterococcus faecium strain, and containing 108 CFU in 1 ml of product. Inoculation of bacteria from patient's feces on selective nutritional medium is performed, with further culture growing in selective nutritional medium, identification and selection of colonies, typical for Enterococcus faecium, obtaining pure culture of Enterococcus faecium and specification of species and content of pathogenecity factors by method of polymerase chain reaction, selection of apatogenic clones of Enterococcus faecium, corresponding to standards of genetic safety and physiological functionality, which are used to prepare lactic starter culture. Autoprobiotic is introduced in dose not less than 100 ml/day, with course constituting not fewer than 10 days. Selected apathogenic clones of Enterococcus faecium are deposited in cryostorage at temperature not higher than -75°C with storage term not longer than 1 year. Enterococcus-agar is used as selective nutritional medium.

EFFECT: method makes it possible to increase efficiency of prophylaxis of PI-IBS patients due to reduction of its development frequency.

3 cl, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely represents composition, which contains mixture of particles of hydrophobic silicon dioxide aerogel, which have specific area of surface per weight unit (Sw) in range from 500 to 1500 m2/g and size, expressed in form of volume mean diameter (D[0.5]), in range from 1 to 1500 mcm, and at least one first linear silicone oil, which has viscosity higher than 50 mm2/s, and at least second and third linear silicone oils, and each of them has viscosity lower than or equal 50 mm2/s.

EFFECT: mixture of particles of silicon dioxide aerogel and linear oils provides possibility of obtaining compositions, which provide comfort and smoothness of skin after application and have dullness and "soft focus"-adding properties.

23 cl, 8 ex

Up!